Clinic
Middlesex Hospital
Middlesex Hospital was paid $116.08M by Medicaid between Jan 2018 and Dec 2024, across 506 billing codes. Its largest line is 99285, emergency room visit (most serious) — 20% of everything it billed.
33Billing provider infoMIDDLESEX HOSPITAL
MIDDLETOWN, CT 06457
MIDDLETOWN, CT 06457
33aNPI1760454334assigned 02/07/2006
33bProvider typeEmergency Care Clinic/Center
28Total paid$116.08M
24GClaims2,850,102
24DCodes billed506
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Care Clinic/Center providers in Connecticut
Rank by total paid#2 of 6
Median peer was paid$80.66M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 368,860 | $16.05M | |
| 2019 | 378,557 | $17.11M | |
| 2020 | 380,679 | $13.48M | |
| 2021 | 473,528 | $17.34M | |
| 2022 | 434,309 | $17.58M | |
| 2023 | 451,771 | $18.19M | |
| 2024incomplete | 362,398 | $16.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 54,416 | 42,450 | $23.65M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 51,112 | 42,412 | $12.84M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 67,461 | 57,724 | $12.62M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.5% | 93,711 | 26,966 | $5.23M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.1% | 36,926 | 29,934 | $4.79M |
| H2019 | Therapeutic behavioral services, billed per 15 minutesTherapeutic behavioral services, per 15 minutes | 3.2% | 14,530 | 2,551 | $3.66M |
| S9480 | Intensive outpatient psychiatric services, per diem | 2.2% | 24,109 | 4,083 | $2.56M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.1% | 35,020 | 18,132 | $2.49M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 12,882 | 10,927 | $2.20M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.3% | 2,880 | 2,448 | $1.49M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 26,078 | 21,546 | $1.46M |
| T1017 | Case management, billed per 15 minutesTargeted case management, each 15 minutes | 1.3% | 11,519 | 2,477 | $1.45M |
494 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 15,775 | $1.39M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 11,387 | $1.37M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 12,361 | $1.36M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 28,916 | $1.35M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 30,575 | $1.28M |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 27,177 | $1.26M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 11,575 | $1.23M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.0% | 21,831 | $1.19M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 2,794 | $1.01M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 10,290 | $1.01M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 55,358 | $1.00M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 10,580 | $978K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,003 | $975K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 10,441 | $920K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,161 | $739K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,288 | $727K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,257 | $719K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,925 | $708K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,470 | $601K |
| 97161 | <1% | 10,801 | $537K | |
| 76641 | <1% | 6,267 | $490K | |
| 93975 | <1% | 2,499 | $473K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,397 | $423K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,032 | $404K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 22,064 | $398K |
| 97035 | <1% | 5,886 | $397K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 808 | $388K |
| 0240U | <1% | 3,556 | $387K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 23,059 | $386K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,436 | $385K |
| 80053 | Comprehensive metabolic panel | <1% | 103,914 | $353K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 7,175 | $348K |
| 88342 | <1% | 5,350 | $345K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,913 | $345K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 36,318 | $339K |
| 86900 | <1% | 10,572 | $335K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,574 | $329K |
| 77065 | Tomosynthesis, mammo | <1% | 3,681 | $327K |
| 80061 | Lipid panel | <1% | 38,635 | $312K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,015 | $306K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,974 | $305K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,842 | $302K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 22,573 | $297K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 2,805 | $288K |
| 77066 | Tomosynthesis, mammo | <1% | 2,861 | $280K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,396 | $277K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 149,525 | $274K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,110 | $273K |
| 76830 | Ultrasound, transvaginal | <1% | 2,897 | $266K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,712 | $259K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,905 | $251K |
| 94060 | <1% | 1,632 | $248K | |
| 97165 | <1% | 4,404 | $240K | |
| 71250 | <1% | 4,920 | $235K | |
| 93971 | <1% | 4,117 | $234K | |
| 74183 | <1% | 1,259 | $226K | |
| 76536 | <1% | 3,486 | $221K | |
| 76642 | <1% | 4,092 | $212K | |
| 97162 | <1% | 5,093 | $206K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 13,139 | $203K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 572 | $203K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,850 | $196K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,419 | $195K |
| 72141 | <1% | 1,094 | $182K | |
| 59025 | Fetal non-stress test | <1% | 1,312 | $179K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,962 | $176K |
| 70496 | <1% | 1,160 | $161K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,974 | $156K |
| 64615 | <1% | 954 | $146K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,234 | $146K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,052 | $137K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,457 | $137K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 10,274 | $134K |
| 76801 | <1% | 1,404 | $134K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,411 | $130K |
| 36415 | Collection of venous blood by venipuncture | <1% | 172,780 | $128K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,433 | $127K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,202 | $126K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 238 | $122K |
| 95811 | <1% | 184 | $115K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 23,237 | $113K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,724 | $111K |
| 76770 | <1% | 1,957 | $107K | |
| 73221 | <1% | 684 | $106K | |
| 29515 | <1% | 864 | $104K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,675 | $103K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,682 | $100K |
| 97014 | <1% | 1,246 | $99K | |
| 77080 | <1% | 1,271 | $98K | |
| 72110 | <1% | 1,606 | $96K | |
| 73564 | <1% | 1,475 | $96K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 7,168 | $93K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,858 | $93K |
| 97113 | <1% | 1,515 | $92K | |
| 71271 | <1% | 1,004 | $89K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 45,329 | $83K |
| 82607 | <1% | 11,117 | $83K | |
| 95819 | <1% | 642 | $79K | |
| 87660 | <1% | 4,748 | $77K | |
| 87510 | <1% | 4,748 | $77K | |
| 87480 | <1% | 4,748 | $77K | |
| 86803 | <1% | 8,455 | $75K | |
| 86618 | <1% | 6,579 | $74K | |
| 93970 | <1% | 705 | $73K | |
| 82728 | <1% | 11,130 | $73K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 991 | $73K |
| 0001A | <1% | 2,380 | $72K | |
| 0002A | <1% | 2,033 | $72K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,159 | $67K |
| 86780 | <1% | 6,242 | $65K | |
| 29505 | <1% | 606 | $65K | |
| 72100 | <1% | 3,022 | $64K | |
| 73030 | <1% | 4,731 | $62K | |
| 84439 | <1% | 12,861 | $60K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,464 | $59K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 284 | $57K |
| 97116 | <1% | 4,037 | $56K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,247 | $54K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 534 | $53K |
| 73630 | <1% | 4,906 | $52K | |
| 74019 | <1% | 1,547 | $50K | |
| 83970 | <1% | 2,708 | $47K | |
| 73502 | <1% | 3,525 | $45K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 3,921 | $44K |
| 86480 | <1% | 1,192 | $44K | |
| 87070 | <1% | 13,140 | $43K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 47,616 | $43K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,975 | $41K |
| 95911 | <1% | 107 | $41K | |
| 73610 | <1% | 4,507 | $40K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,164 | $39K |
| 82746 | <1% | 5,745 | $38K | |
| 82947 | <1% | 20,398 | $38K | |
| 70491 | <1% | 240 | $37K | |
| 84403 | <1% | 1,957 | $37K | |
| 77336 | <1% | 829 | $36K | |
| 70486 | <1% | 1,441 | $36K | |
| 10061 | <1% | 126 | $35K | |
| 96367 | <1% | 1,324 | $35K | |
| 73130 | <1% | 3,712 | $34K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,754 | $29K |
| 73110 | <1% | 3,035 | $29K | |
| 72070 | <1% | 747 | $28K | |
| 83540 | <1% | 8,970 | $28K | |
| 86038 | <1% | 3,939 | $27K | |
| 77062 | <1% | 2,374 | $27K | |
| 86235 | <1% | 697 | $27K | |
| 77061 | <1% | 2,447 | $27K | |
| 83550 | <1% | 6,737 | $27K | |
| 73562 | <1% | 4,380 | $27K | |
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation | <1% | 35 | $25K |
| 86617 | <1% | 2,007 | $25K | |
| 82784 | <1% | 3,566 | $25K | |
| 87186 | <1% | 8,709 | $25K | |
| 74018 | <1% | 1,226 | $25K | |
| 93880 | <1% | 327 | $25K | |
| 87340 | <1% | 4,987 | $25K | |
| 76775 | <1% | 563 | $24K | |
| 72052 | <1% | 318 | $24K | |
| 10060 | <1% | 148 | $23K | |
| 87077 | <1% | 8,190 | $23K | |
| 77334 | <1% | 67 | $22K | |
| 86753 | <1% | 1,907 | $21K | |
| 73140 | <1% | 2,204 | $21K | |
| 73700 | <1% | 469 | $20K | |
| 86140 | <1% | 9,475 | $20K | |
| 86666 | <1% | 2,426 | $19K | |
| 84146 | <1% | 1,414 | $19K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 305 | $18K |
| 83735 | <1% | 21,661 | $18K | |
| 98968 | <1% | 354 | $17K | |
| 98967 | <1% | 460 | $17K | |
| 86200 | <1% | 2,339 | $17K | |
| 96137 | <1% | 180 | $17K | |
| 19083 | <1% | 33 | $17K | |
| 72040 | <1% | 963 | $16K | |
| 95806 | <1% | 166 | $16K | |
| 84702 | <1% | 3,466 | $16K | |
| 84480 | <1% | 1,656 | $15K | |
| 72197 | <1% | 60 | $15K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 160 | $15K |
| 82043 | <1% | 5,233 | $14K | |
| 92610 | <1% | 398 | $14K | |
| 73080 | <1% | 1,685 | $14K | |
| 71101 | <1% | 924 | $14K | |
| 83516 | <1% | 1,624 | $13K | |
| 87147 | <1% | 5,223 | $13K | |
| 80076 | <1% | 5,563 | $13K | |
| 84425 | <1% | 922 | $13K | |
| 97166 | <1% | 345 | $12K | |
| 74246 | <1% | 85 | $12K | |
| 87081 | <1% | 3,243 | $12K | |
| 87631 | <1% | 133 | $12K | |
| 85027 | <1% | 4,328 | $12K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 53 | $11K |
| 76882 | <1% | 247 | $11K | |
| 83655 | <1% | 1,035 | $11K | |
| 80164 | <1% | 2,058 | $11K | |
| 70498 | <1% | 1,061 | $11K | |
| 85652 | <1% | 8,766 | $10K | |
| 82570 | <1% | 5,271 | $10K | |
| 92523 | <1% | 68 | $10K | |
| 86376 | <1% | 1,216 | $10K | |
| 96131 | <1% | 51 | $10K | |
| 88304 | <1% | 1,653 | $10K | |
| 86430 | <1% | 3,219 | $9K | |
| 83690 | <1% | 26,574 | $9K | |
| 97010 | <1% | 131 | $9K | |
| 88307 | <1% | 404 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 28,885 | $9K |
| 84481 | <1% | 968 | $9K | |
| 81001 | <1% | 26,486 | $8K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 399 | $8K |
| 86706 | <1% | 1,248 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 158 | $8K |
| 83880 | <1% | 4,981 | $8K | |
| 80074 | <1% | 257 | $8K | |
| 85610 | <1% | 24,048 | $8K | |
| 87625 | <1% | 272 | $8K | |
| 86800 | <1% | 782 | $7K | |
| 83001 | <1% | 545 | $7K | |
| 87899 | <1% | 881 | $7K | |
| 84165 | <1% | 1,822 | $7K | |
| 93308 | <1% | 59 | $7K | |
| 84550 | <1% | 4,977 | $7K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 148 | $7K |
| 96130 | <1% | 101 | $7K | |
| 82105 | <1% | 655 | $7K | |
| 93798 | <1% | 73 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 18 | $6K |
| 72131 | <1% | 114 | $6K | |
| 84402 | <1% | 329 | $6K | |
| 86762 | <1% | 1,814 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 215 | $6K |
| 86364 | <1% | 693 | $6K | |
| 73560 | <1% | 522 | $6K | |
| 86769 | <1% | 189 | $6K | |
| 74220 | <1% | 55 | $6K | |
| 82550 | <1% | 3,546 | $5K | |
| 86334 | <1% | 698 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 44 | $5K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 24 | $5K |
| 73590 | <1% | 840 | $5K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 92 | $5K |
| 82950 | <1% | 1,273 | $5K | |
| 99406 | <1% | 1,008 | $5K | |
| 83615 | <1% | 2,699 | $5K | |
| 85730 | <1% | 5,432 | $5K | |
| 87046 | <1% | 765 | $5K | |
| 86039 | <1% | 684 | $5K | |
| 81003 | <1% | 17,389 | $4K | |
| 81025 | <1% | 8,869 | $4K | |
| 80178 | <1% | 1,283 | $4K | |
| 36430 | <1% | 75 | $4K | |
| 87205 | <1% | 3,976 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 137 | $4K |
| 82565 | <1% | 4,961 | $4K | |
| 82248 | <1% | 2,046 | $4K | |
| 83721 | <1% | 802 | $4K | |
| 74021 | <1% | 79 | $4K | |
| 82247 | <1% | 3,518 | $4K | |
| 74230 | <1% | 63 | $4K | |
| 84100 | <1% | 6,060 | $4K | |
| 96136 | <1% | 115 | $3K | |
| 86787 | <1% | 419 | $3K | |
| 87045 | <1% | 765 | $3K | |
| 87209 | <1% | 447 | $3K | |
| 84153 | <1% | 391 | $3K | |
| 86225 | <1% | 388 | $3K | |
| 84450 | <1% | 3,746 | $3K | |
| 82533 | <1% | 282 | $3K | |
| 83002 | <1% | 213 | $3K | |
| 83520 | <1% | 379 | $3K | |
| 87493 | <1% | 216 | $3K | |
| 0004A | <1% | 81 | $3K | |
| 73660 | <1% | 291 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,973 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 28 | $2K |
| 84703 | <1% | 15,315 | $2K | |
| 0012A | <1% | 96 | $2K | |
| 95910 | <1% | 17 | $2K | |
| 99442 | <1% | 321 | $2K | |
| 82670 | <1% | 97 | $2K | |
| 0064A | <1% | 57 | $2K | |
| 87177 | <1% | 447 | $2K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,468 | $2K |
| 84156 | <1% | 1,885 | $2K | |
| 25600 | <1% | 17 | $2K | |
| 87015 | <1% | 647 | $2K | |
| 87075 | <1% | 1,344 | $2K | |
| 84630 | <1% | 279 | $2K | |
| 82150 | <1% | 515 | $2K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,895 | $2K |
| 84590 | <1% | 253 | $2K | |
| 0011A | <1% | 252 | $2K | |
| 87469 | <1% | 92 | $2K | |
| 74247 | <1% | 12 | $2K | |
| 82040 | <1% | 3,064 | $2K | |
| 83525 | <1% | 185 | $2K | |
| 73090 | <1% | 268 | $2K | |
| 82525 | <1% | 211 | $2K | |
| 92611 | <1% | 49 | $2K | |
| 82140 | <1% | 772 | $2K | |
| 86160 | <1% | 150 | $2K | |
| 82310 | <1% | 3,002 | $1K | |
| 0071A | <1% | 38 | $1K | |
| 87400 | <1% | 2,140 | $1K | |
| 85014 | <1% | 2,016 | $1K | |
| 85379 | <1% | 5,348 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 23,233 | $1K |
| 80050 | General health panel | <1% | 1,569 | $1K |
| J3490 | Unclassified drugs | <1% | 60,140 | $1K |
| 0072A | <1% | 30 | $1K | |
| 73521 | <1% | 40 | $1K | |
| 85018 | <1% | 2,310 | $1K | |
| 90839 | <1% | 1,702 | $1K | |
| 86255 | <1% | 175 | $1K | |
| 84484 | <1% | 26,797 | $1K | |
| 80051 | <1% | 842 | $985.71 | |
| 86850 | <1% | 7,347 | $942.60 | |
| 84134 | <1% | 243 | $904.80 | |
| 73120 | <1% | 28 | $833.37 | |
| 86003 | <1% | 14 | $811.74 | |
| C9399 | Unclassified drugs or biologicals | <1% | 519 | $808.03 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 1,072 | $753.00 |
| 86765 | <1% | 70 | $750.91 | |
| 12001 | <1% | 1,918 | $750.57 | |
| 86735 | <1% | 69 | $747.60 | |
| 86308 | <1% | 496 | $714.06 | |
| 83883 | <1% | 69 | $661.98 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 951 | $650.00 |
| 84436 | <1% | 221 | $644.26 | |
| 87207 | <1% | 710 | $624.00 | |
| 87040 | <1% | 7,824 | $566.99 | |
| 84155 | <1% | 1,796 | $563.03 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,456 | $549.13 |
| 87427 | <1% | 58 | $547.84 | |
| 86923 | <1% | 33 | $519.72 | |
| 70544 | <1% | 27 | $517.83 | |
| 82378 | <1% | 41 | $507.36 | |
| 80159 | <1% | 28 | $459.16 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,834 | $450.71 |
| Q3014 | Telehealth originating site facility fee | <1% | 28 | $360.52 |
| 86705 | <1% | 82 | $360.00 | |
| 84075 | <1% | 2,739 | $356.42 | |
| 84460 | <1% | 3,858 | $355.22 | |
| 82627 | <1% | 26 | $318.45 | |
| 84112 | <1% | 18 | $307.60 | |
| 96376 | <1% | 10,470 | $305.71 | |
| 83993 | <1% | 17 | $300.00 | |
| 12002 | <1% | 797 | $296.95 | |
| 99443 | <1% | 60 | $285.58 | |
| 82977 | <1% | 93 | $277.76 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 40,768 | $275.63 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,724 | $263.04 |
| 86696 | <1% | 12 | $258.72 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 26,204 | $256.01 |
| 84520 | <1% | 2,790 | $254.07 | |
| 83605 | <1% | 8,837 | $232.49 | |
| 74175 | <1% | 24 | $223.92 | |
| 90714 | <1% | 3,347 | $217.87 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 521 | $216.54 |
| 83521 | <1% | 15 | $197.76 | |
| 85045 | <1% | 135 | $194.82 | |
| 82747 | <1% | 16 | $181.94 | |
| 86304 | <1% | 17 | $178.83 | |
| 86695 | <1% | 12 | $176.40 | |
| 87338 | <1% | 12 | $151.03 | |
| 87449 | <1% | 19 | $148.85 | |
| 86704 | <1% | 14 | $138.12 | |
| 84132 | <1% | 267 | $132.56 | |
| 72170 | <1% | 41 | $122.61 | |
| 0054A | <1% | 33 | $120.00 | |
| 86141 | <1% | 13 | $111.24 | |
| 82010 | <1% | 1,173 | $101.40 | |
| 84295 | <1% | 2,620 | $98.76 | |
| 82803 | <1% | 1,348 | $94.62 | |
| 87807 | <1% | 82 | $93.25 | |
| 88300 | <1% | 14 | $77.61 | |
| 80175 | <1% | 12 | $75.96 | |
| 88313 | <1% | 1,647 | $73.89 | |
| 88173 | <1% | 61 | $55.57 | |
| 80177 | <1% | 16 | $50.64 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,567 | $47.24 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 69 | $47.00 |
| 88108 | <1% | 157 | $44.46 | |
| 29125 | <1% | 850 | $41.58 | |
| 82800 | <1% | 133 | $40.40 | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 1,685 | $39.30 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,086 | $37.42 |
| C1769 | Guide wire | <1% | 831 | $37.02 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,395 | $30.80 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,931 | $26.80 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 9,923 | $26.39 |
| 82435 | <1% | 2,096 | $26.30 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,074 | $22.98 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 6,639 | $22.97 |
| 86901 | <1% | 10,580 | $21.63 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,624 | $17.40 |
| A9270 | Non-covered item or service | <1% | 6,956 | $16.67 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 24,797 | $15.74 |
| 85049 | <1% | 60 | $14.96 | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,903 | $14.82 |
| 86703 | <1% | 555 | $13.71 | |
| 84145 | <1% | 203 | $12.90 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,245 | $12.30 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,053 | $12.13 |
| 82374 | <1% | 2,082 | $12.01 | |
| 87210 | <1% | 17 | $11.70 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,457 | $9.36 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,830 | $8.89 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 721 | $8.16 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 1,045 | $8.01 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 15 | $8.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,092 | $7.74 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,170 | $7.54 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15,973 | $6.87 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,762 | $6.11 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,870 | $5.25 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,589 | $4.97 |
| 89050 | <1% | 16 | $4.52 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 711 | $3.89 |
| 94727 | <1% | 1,462 | $2.64 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,148 | $2.40 |
| 94729 | <1% | 1,484 | $1.97 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 7,853 | $1.94 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 671 | $1.32 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 9,185 | $0.02 |
| 88341 | 0% | 1,966 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 11,589 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 3,726 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 1,827 | $0.00 |
| 95886 | 0% | 1,600 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 4,051 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 348 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 576 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 377 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 488 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 731 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 417 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 630 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 168 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 214 | $0.00 |
| 91301 | 0% | 308 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 18 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 411 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 461 | $0.00 |
| 0204U | 0% | 64 | $0.00 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 134 | $0.00 |
| 36410 | 0% | 292 | $0.00 | |
| 36000 | 0% | 49 | $0.00 | |
| 91305 | 0% | 64 | $0.00 | |
| 91306 | 0% | 24 | $0.00 | |
| 29130 | 0% | 13 | $0.00 | |
| 91307 | 0% | 69 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 25 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 110 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 95 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 15 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 17 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 16 | $0.00 |
| 73060 | 0% | 15 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 2,496 | $0.00 |
| 91300 | 0% | 4,396 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 302 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 201 | $0.00 |
| 12011 | 0% | 756 | $0.00 | |
| 99152 | 0% | 727 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 2,820 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 523 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 50 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 371 | $0.00 |
| 76937 | 0% | 114 | $0.00 | |
| 76376 | 0% | 66 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 16 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 628 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,973 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 20 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 315 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 1,746 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 1,346 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 158 | $0.00 |
| 51701 | 0% | 579 | $0.00 | |
| 85520 | 0% | 70 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 60 | $0.00 |
| 76942 | 0% | 26 | $0.00 | |
| 51702 | 0% | 15 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 19 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 220 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 63 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 14 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 36 | $0.00 |
| 76000 | 0% | 61 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCAPECE, VINCENT (CEO PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Middlesex Hospital | Middletown, CT | $7.45M |
| Middlesex Hospital | Middletown, CT | $2.70M |
| Middlesex Hospital | Middletown, CT | $2.02M |
| Middlesex Hospital | Middletown, CT | $700K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.